Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma

Table 1 Baseline characteristics of treated patients.

ID Number	Gender	Age (years)	KPS (%)	HLA-A2	LDH	Stage IV	Sites of Metastasis	Prior Cytokine Therapy	Prior Chemotherapy
0001–1103	M	49	80	+	169	M1b	Abdominal wall, thorax	IL2	Yes
0002–2101	M	30	90	+	130	M1b	Lung	IL2	No
0002–2102	F	39	80	+	429	M1c	Skin, lymph nodes, liver	IFNα2b	Yes
0003–3101	M	44	90	-	575	M1c	Skin, lymph nodes, lung	IL2 and IFNα2b	Yes
0003–3102	M	67	80	+	1388	M1c	Lymph nodes, skin, lung, liver	IL2 and IFNα2b	Yes
0004–4101	M	40	100	+	132	M1a	Skin	IFNα2b	No
0004–4102	M	36	90	+	333	M1c	Lymph nodes, spleen, liver	IFNα2b	Yes
0004–4103	F	54	90	-	94	M1c	Skin, liver	IFNα2b	No
0004–4104	M	76	90	-	282	M1c	Skin, lung	IFNα2b	No

ID = identification. KPS = Karnofsky performance status. LDH = lactate dehydrogenase (on Day 1 of Cycle 1). M = male. F = female. IFN = interferon. IL2 = interleukin-2.